Clinical Trial Detail

NCT ID NCT01855750
Title A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

diffuse large B-cell lymphoma

Therapies

Ibrutinib

Rituximab

Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate

Age Groups: adult

No variant requirements are available.